Skip to main content
. 2017 Feb 7;5(4):143–164. doi: 10.2217/ijh-2016-0011

Table 3. . First-generation and second-generation Fms-like tyrosine 3 inhibitors under clinical investigation in acute myeloid leukemia patients.

Inhibitor Structure Target IC50 against FLT3–ITD (nM) Trial phase Company
Lestaurtinib (CEP-701) graphic file with name ijh-05-143-T3a.gif JAK2, FLT3, TrK A 3 III Cephalon
Midostaurin (PKC 412) graphic file with name ijh-05-143-T3b.gif FLT3, c-KIT, PDGFRB, VEGFR <10 II/III Novartis
Sunitinib (Sutent) graphic file with name ijh-05-143-T3c.gif FLT3, c-KIT, KDR, PDGFR 4 I/II Pfizer
Tandutinib (MLN 518) graphic file with name ijh-05-143-T3d.gif FLT3, PDGFR, c-KIT 220 I Millenium Pharmaceuticals
Crenolanib (CP-868–596) graphic file with name ijh-05-143-T3e.gif FLT3, PDGFR 1–2 II/III Arog Pharmaceuticals
Gilteritinib (ASPO 2215) graphic file with name ijh-05-143-T3f.gif FLT3, AXL 0.29 III Astellas Pharma
Ponatinib (AP 24 534, Iclusig) graphic file with name ijh-05-143-T3g.gif BCR/ABL, FLT3, c-KIT, FGFR1, PDGFRA 4 I/II ARIAD Pharmaceuticals
Quizartinib (AC 220) graphic file with name ijh-05-143-T3h.gif FLT3, c-KIT, PDGFRA 1.1 II AMBIT Biosciences
Sorafenib (Nexavar) graphic file with name ijh-05-143-T3i.gif FLT3, c-KIT, VEGFR, PDGFR, RAF-1 2 III Bayer and Onyx Pharmaceuticals